Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy J Butcher

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Neurology|May 13, 2018
Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2Erik Boot, Nancy J Butcher, Sean Udow, et al.
Eclinicalmedicine|October 25, 2023
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsOriana Ciani, Anthony M Manyara, Philippa Davies, et al.
JAMA Psychiatry|February 26, 2015
Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndromeJacob A S Vorstman, Elemi J Breetvelt, Sasja N Duijff, et al.
Orphanet Journal of Rare Diseases|January 16, 2020
Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a reviewMichael Pugliese, Kylie Tingley, Andrea Chow, et al.
Pediatrics|July 16, 2021
Core Outcome Sets for Medium-Chain Acyl-CoA Dehydrogenase Deficiency and PhenylketonuriaMichael Pugliese, Kylie Tingley, Andrea Chow, et al.
The Lancet. Child & Adolescent Health|June 12, 2026
CONSORT-Children and Adolescents (CONSORT-C) 2026 extension statement: enhancing the reporting and impact of paediatric randomised trialsAmi Baba, Maureen Smith, Beth K Potter, et al.
JAMA Pediatrics|February 24, 2026
CONSORT-Children and Adolescents (CONSORT-C) 2026 Extension Statement: Enhancing the Reporting and Impact of Pediatric Randomized TrialsAmi Baba, Maureen Smith, Beth K Potter, et al.
The Lancet. Child & Adolescent Health|June 12, 2026
SPIRIT-Children and Adolescents (SPIRIT-C) 2026 extension statement: enhancing the reporting and usefulness of paediatric randomised trial protocolsAmi Baba, Maureen Smith, Beth K Potter, et al.
JAMA Pediatrics|February 24, 2026
SPIRIT-Children and Adolescents (SPIRIT-C) 2026 Extension Statement: Enhancing the Reporting and Usefulness of Pediatric Randomized Trial ProtocolsAmi Baba, Maureen Smith, Beth K Potter, et al.
BMJ (Clinical Research Ed.)|April 14, 2025
CONSORT 2025 statement: updated guideline for reporting randomised trialsSally Hopewell, An-Wen Chan, Gary S Collins, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Neurology|May 13, 2018
Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2Erik Boot, Nancy J Butcher, Sean Udow, et al.
Eclinicalmedicine|October 25, 2023
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trialsOriana Ciani, Anthony M Manyara, Philippa Davies, et al.
JAMA Psychiatry|February 26, 2015
Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndromeJacob A S Vorstman, Elemi J Breetvelt, Sasja N Duijff, et al.
Orphanet Journal of Rare Diseases|January 16, 2020
Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a reviewMichael Pugliese, Kylie Tingley, Andrea Chow, et al.
Pediatrics|July 16, 2021
Core Outcome Sets for Medium-Chain Acyl-CoA Dehydrogenase Deficiency and PhenylketonuriaMichael Pugliese, Kylie Tingley, Andrea Chow, et al.
The Lancet. Child & Adolescent Health|June 12, 2026
CONSORT-Children and Adolescents (CONSORT-C) 2026 extension statement: enhancing the reporting and impact of paediatric randomised trialsAmi Baba, Maureen Smith, Beth K Potter, et al.
JAMA Pediatrics|February 24, 2026
CONSORT-Children and Adolescents (CONSORT-C) 2026 Extension Statement: Enhancing the Reporting and Impact of Pediatric Randomized TrialsAmi Baba, Maureen Smith, Beth K Potter, et al.
The Lancet. Child & Adolescent Health|June 12, 2026
SPIRIT-Children and Adolescents (SPIRIT-C) 2026 extension statement: enhancing the reporting and usefulness of paediatric randomised trial protocolsAmi Baba, Maureen Smith, Beth K Potter, et al.
JAMA Pediatrics|February 24, 2026
SPIRIT-Children and Adolescents (SPIRIT-C) 2026 Extension Statement: Enhancing the Reporting and Usefulness of Pediatric Randomized Trial ProtocolsAmi Baba, Maureen Smith, Beth K Potter, et al.
BMJ (Clinical Research Ed.)|April 14, 2025
CONSORT 2025 statement: updated guideline for reporting randomised trialsSally Hopewell, An-Wen Chan, Gary S Collins, et al.
Pageof 10